Compare · ALNA vs JNJ
ALNA vs JNJ
Side-by-side comparison of Allena Pharmaceuticals Inc. (ALNA) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALNA and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $558.86B, about 18403.3x ALNA ($30.4M).
- JNJ has hit the wire 8 times in the past 4 weeks while ALNA has been quiet.
- JNJ has more recent analyst coverage (25 ratings vs 0 for ALNA).
- Company
- Allena Pharmaceuticals Inc.
- Johnson & Johnson
- Price
- -
- -
- Market cap
- $30.4M
- $558.86B
- 1M return
- -
- +4.36%
- 1Y return
- -
- +49.56%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 0
- 8
- Recent ratings
- 0
- 25
Allena Pharmaceuticals Inc.
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and moderate to severe chronic kidney diseases. Allena Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Newton, Massachusetts.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest ALNA
- SEC Form SEC STAFF ACTION filed by Allena Pharmaceuticals Inc.
- SEC Form SC 13G/A filed by Allena Pharmaceuticals Inc. (Amendment)
- SEC Form NT 10-Q filed by Allena Pharmaceuticals Inc.
- SEC Form 25-NSE filed by Allena Pharmaceuticals Inc.
- Allena Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Why Korn Ferry Is Trading Lower By Over 8%, Here Are 40 Stocks Moving In Wednesday's Mid-Day Session
- Allena Pharmaceuticals shares are trading higher after the stock dipped on Tuesday following news the company has filed for bankruptcy.
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Why Coupa Software Is Trading Higher By Over 12%; Here Are 24 Stocks Moving Premarket
- Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday
Latest JNJ
- Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
- SEC Form SD filed by Johnson & Johnson
- SEC Form 13F-HR filed by Johnson & Johnson
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research